Special Issue "PI3 Kinase Inhibitors"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2012)
Dr. Philip Thompson (Website)
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical, Sciences, Monash University, Parkville 3052, Australia
Phosphoinositide 3-kinases (PI3K) are important cell signalling enzymes, generating key second messengers that regulate a myriad of cellular functions. In recent years, potential applications for inhibitors have emerged in the treatment of cancer, cardiovascular disease, inflammatory diseases and autoimmune diseases. This special issue hopes to highlight the challenges and lessons learned in going from "hit to lead" and "lead to candidate" when developing targets for PI3K. Articles that deal with the concepts and results of specific strategic choices in PI3K inhibitor pharmaceutical development are encouraged. These include design approach (eg library screening, structure based design), isoform selectivity, scaffold selection, ADME properties or in vitro/in vivo models. In this issue, I hope novel contributions can be made to the medicinal chemistry knowledge base with original papers or critical reviews.
Dr. Philip Thompson
- PI3 kinase
- cell signaling
- cancer therapeutics
- lipid kinase
- immune disease